BioSeek, Inc. Licenses Two Novel Anti-Inflammatory Peptides

BURLINGAME, Calif.--(BUSINESS WIRE)--BioSeek, Inc., a pioneer in the application of predictive human biology to drug discovery, announced today that it has exclusively licensed two novel anti-inflammatory peptides from Amylin Pharmaceuticals, Inc. The two novel peptides were identified as candidates for development by BioSeek as a result of an ongoing joint research collaboration initiated between the two companies in 2007. These two peptides will be the basis for proprietary optimization and development programs at BioSeek for potential indications outside of Amylin’s core therapeutic focus.

Back to news